RECEIVED

JUN 2 8 2002



Approved for use III to be the Control of the Contr

Substitute for form 1449AFTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	TABLE OND CONTROL HEIMSCI.
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et
	al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

		U.S. Patent Do	cument				
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy Pages, Columns, Lin where relevant passa or relevant figures app		
54		4,500,525		Winters , et al.	02-19-1985		
		5,264,576		Shutske, et al.	11-23-1993		
		5,776,718		Palmer, et al.	07-07-1998		
		5,976,858		Palmer, et al.	11-02-1999		
5v		6,030,946		Klaus, et al.	02-29-2000		
					•		
m ni			0,5,7				

FOREIGN PATENT DOCUMENTS Date of Publication Foreign Patent Document Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner mm-dd-yyyy тв Applicant of Cited Document figures appear Initials Number⁴ KindCode5 Office³ No.1 EΡ 382637 В1 Laboratorios del Dr. Esteve, S.A. 07-28-1993 EP 502786 **B**1 Laboratorios del Dr. Esteve, S.A. 04-24-1996 EP 655248 В1 Laboratorios del Dr. Esteve, S.A. 09-15-1999 wo 97/21439 Α1 Laboratorios del Dr. Esteve, S.A. 06-19-1997 wo 99/24460 A2 Novartis AG 05-20-1999

Examiner		Date / / / 7
Signature	ュレ つ	Considered /// O / O

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JUN 2 6 2002

Approved for use theology IV.

U.S. Patent and Trademark Office Late Day 5, no persons are required to respond to a

Substitute for form 1449AIP CONADEMAR

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Examiner Cite of Cited Document where relevant passages of Cited Document Initials Number (if known) or relevant figures appear No.1 mm-dd-yyyy 09-11-2001 6,287,840 В1 Palmer, J. T. et al.

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

					EIGN PATENT DOCUMENTS			
		Foreign	Patent Docume	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴ Ki	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		wo	95/23222	A1	Khepri Pharmaceuticals, Inc.	08-31-1995		
		wo	96/30353	A1	Arris Pharmaceutical Corporation	10-03-1996		
		wo	97/40066	A1	Mass. Institute of Technology - Brigham & Women's Hospital	10-30-1997		
		wo	99/58153	A1	Brigham & Women's Hospital	11-18-1999		

Examiner	Date
Signature	Considered
	00110100100

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

JUN 2 6 2002
PTO/SEGGA (68-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Officer U.S. PERABUMENT OF COMMERCE to a collection of information unless till districts and 10 MR collection of

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless adding a s	EVEND COMPACTOR INTERVENTION
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
14		ALLEN, E.M. et al, "Reversible Cathepsin S (CATS) Inhibitors Block Invariant Chain Degradation Both In Vitro and In Vivo" Inflammation Research (2001) Sup 3, Vol. 50, p S159 abstr. 10/04	
		BROMME, D. et al.; "Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors"; Biochem. J. (1996) 315:85-89	
		CHAPMAN, H.A. et al.; "Emerging Roles For Cysteine Proteases in Human Biology"; Annu. Rev. Physiol. (1997) 59:63-88	
		CHAPMAN, H.A. "Endosomal Proteolysis and MHC Class II Function"; Curr. Opin. Immunol. (1998) 10:93-102	
		HONEY, K. et al.; "Role of Lysosomal Cysteine Proteinases in Antigen Presentation to CD4 T Cells"; Inflammation Research (2001) Sup.3, Vol. 50, pS159 abstr. 10/01	
		LI, W. et al.; ""Tissue Specific Expression of Cathepsins and Antigen Presentation"; Inflammation Research (2001) Sup 3, Vol. 50 p S159 abstr. 10/02	
		MAGILL, C. et al.; "Cysteine Proteases in Antigen Presentation and Models of Inflammation"; Inflammation Research (2001) Sup 3, Vol 50, p S159, abstr. 10/03	
		MAURER, D. et al.; "Fce Receptor I on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S- Dependent Pathway of MHC Class II Presentation" J. Immunol. (1998) 161:2731-2739	
		MCGRATH, M.E. et al.: "Crystal structure of human cathepsin S"; Protein Science (1998) 7:1294-1302	
		NAKAGAWA, T. Y. et al.; "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice"; Immunity (1999) 10:207-217	
		NAKAGAWA, T.Y. et al.: "The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation" Immunological Rev. (1999) 172:121-129	
		NERENBERG, J. B. et al.; "Design and Synthesis of N-Alkylated Saccharins as Selective a-1A Adrenergic Receptor Antagonists"; Bioorg. Med. Chem. Lett. (1998) 8:2467-2472	
		PALMER, J. T. et al.; "Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors"; J. Med. Chem. (1995) 38(17):3193-3196	
		PODOLIN, P.L. et al.; "Inhibition of Cathepsin S Blocks Invariant Chain Processing and Antigen-Induced Proliferation In Vitro and Reduces the Severity of Collagen-Induced, Arthritis In Vivo"; Inflammation Research (2001) Sup 3, Vol. 50, p S 159 abstr. 10/05	
		RIESE, R. J. et al.; "Cathepsin S Activity Regulates Antigen Presentation and Immunity"; J. Clin Invest. (1998) 101 (11):2351-2363	
		RIESE, R.J. et al.; ""Cathepsins and Compartmentalization in Antigen Presentation"; Curr. Opin. Immunol. (2000) 12:107-113	
		SHI, Guo-Ping, et al.; "Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development"; Immunity (1999) 10:197-206	
		SPERO, D. et al.; "Design and Synthesis of Novel Cathepsin S Inhibitors"; Inflammation Research (2001) Sup. 3, Vol. 50, p S206, abstr. 079	
		VILLADANGOS, J. A. et al.; "Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism" J. Exp. Med. (1997) 186(4):549-560	
		VILLADANGOS, J. A. et al.; "Proteases Involved in MHC Class II Antigen Presentation" Immunological Rev. (1999)172:109- 120	
	n = i	VILLADANGOS, J.A. et al.; "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?"; Immunity (2000) 12:233-239	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



JUN 2 8 2002

Approved for use third U.S. Patent and Trademark Office: U.S. E o a collection of information

995, no persons are required to respond to a

Under the No Swork Reduction A
Substitute for form 1449A/P TRADE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a	Valid Civio Control Humber.
Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy Breitenbucher et al.
	
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's nitials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
60		ANDRONATI, S.A. et al.: "Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]1,2-dihydro-3H-1,4-benzodiazepin-2-ones and1H-indazoles and their affinity for benzodiazepine receptors"; Chemical Abstracts Number (CAN) 122:314528; (1994) 8:126-131	
		BROMME, D, et al.; "High level expression and crystallization of recombinant human cathepsin S"; Protein Science (1996) 5:789-791	-
		EBERLEIN-KONIG, et al.; "Immunohistochemical investigation of the cellular infiltrates at the sites of allergoid-induced late- phase cutaneous reactions associated with pollen allergen-specific immunotherapy";	
		GAGA, et al; "Eosinophil Activation and T Lymphocyte Infiltration in Allergin-Induced Late Phase Skin Reactions and Classical Delayed-Type Hypersensitivity" J. Immunol. (1991) 147:816-822	
		KIRSCHKE, H. et al.; "Cathepsin S"; Handbook of Proteolytic Enzymes; Barrett, A.J.; Rawlings, N.D.; Woessner, J.F., Editors, Academic Press (1998) 621-624	
		RIESE, R.J. et al.; "Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading"; Immunity (1996) 4:357-366	
	,	SINGH, P., et al., "Quantitative Structure-Activity Relationship Studies on a New Class of Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine"; Quant. StructAct. Relat. (1990) 9:29-32	
Sw		WINTERS, G. et al., "Synthesis in Vitro [3H]Prazosin Displacement and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a New Class of Antihypertensive"; J. Med. Chem. (1985) 28(7):934-940	


Examiner Signature	6.11	Date Considered 11/10/23

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

and not considered. Include copy of this form with next communication to applicant.

a couection of information unless it displays a	a valio CMB control number.
Application Number	10/075,673
Filing Date	F bruary 13, 2002
First Named Inventor	J. Guy Breit nbucher t al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

				U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)		Kind Code ²		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
				· · · · · · · · · · · · · · · · · · ·				
	 		- - 					
	-				+			
					•			

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Date of Publication Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant T⁶ Cite mm-dd-yyyy Examiner Applicant of Cited Document figures appear Initials KindCode⁵ Number⁴ Office³ EΡ 0 254 241 A1 Yoshitomi Pharmaceutical 01-27-1988 12-17-1998 wo 98/56785 A1 Sumitomo Pharmaceuticals Co. Ltd.

Examiner Signature	6	[<u></u>		Date Considered	[1]	10/	03	
ACMA MAINTED	I - War I make an	annidared W	the tree or not	citation is in conformance with M	DED 600 Drav	v line throug	n citation	if noten conformance	

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, a Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 1 9 2002

TECH CENTER 1600/2900



COPY OF PAPERS **ORIGINALLY FILED**

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a waird DMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of thiornasion unless it displays a valid Owlo control number.					
Application Number	10/075,673				
Filing Date	F bruary 13, 2002				
First Named Inventor	J. Guy Breitenbuch r et al.				
Group Art Unit	1619				
Examiner Name					
Attorney Docket Number	ORT-1590				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
50		NAKATSUKA, MASASHI et al. "Preparation of pyrazole derivatives as immunosuppressants" Abstrat retrieved from STN Database accession no. 130:52417, Sumitomo Pharmaceuticals Co., Ltd., Japan 1998	
	-		

Examiner Signature	5.10	Date Considered	11	\angle	10	107	
				$\overline{}$			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUL 1 9 2002

TECH CENTER 1600/2900

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

JUL 1 6 2002

COPY OF PAPERS ORIGINALLY FILED

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy
	Breitenbucher et al.
Group Art Unit	1619
Examiner Name	
Attorney Docket Number	ORT-1590

Examiner Initials No.1 Name of Patentee or Applicant of Cited Document Number (if known)

Number Pages, Columns, Lines, where relevant figures appear

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or or relevant figures Examiner Cite T٥ Applicant of Cited Document appear Office³ Number⁴ KindCode⁵ No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T² Examiner Cite title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), No.1 volume-issue number(s), publisher, city and/or country where published PCT Search Report - International Application No. PCT/US01/27479 - Ortho McNeil Pharmaceutical, Inc.

Examiner Signature	5.	VD	Date Considered	(1)	10/	121	
						<u></u>	<i></i>

RECEIVED

JUL 1 9 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

a conection of information unless it displays a	a conection of information unless it displays a valid OMB control number.					
Application Number	10/075,673					
Filing Date	February 13, 2002					
First Named Inventor	J. Guy Breitenbucher					
Group Art Unit	1619					
Examiner Name	Unknown					
Attorney Docket Number	ORT-1590					

		U.S. Patent Do	ocument			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appea

FOREIGN PATENT DOCUMENTS Date of Publication Pages, Columns, Lines, Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear Initials KindCode⁵ Office³ Number⁴ No.1 wo 01/40204 One Pharmaceutical Co. 06/07/2001 WO 01/19796 Α Axvs Pharmaceuticals, Inc. 03/22/2001 wo 01/09110 Α 02/08/2001 Boehringer Ingelheim Pharmaceuticals, Inc. wo 00/55144 Α Axys Pharmaceuticals, Inc. 09/21/2000 wo 00/51998 Α 09/08/2000 Boehringer Ingelheim Pharmaceuticals, Inc. wo 00/49008 08/24/2000 Α Astrazeneca AB wo 99/48911 09/30/1999 Synphar Laboratories, Inc.

Examiner		Date	(1/0/07
Signature	5.1/0	Considered	U/U/U

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Office, Washington, DC 20231.

Office, Washington, DC 20231.

Office, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O P E VO TO STEAM & STEAM & TRANSPORT

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/075,673
Filing Date	February 13, 2002
First Named Inventor	J. Guy
	Breitenbucher
Group Art Unit	1619
Examiner Name	unknown
Attorney Docket Number	ORT-1590
OCUMENTS	
	Filing Date First Named Inventor Group Art Unit Examiner Name

		Name of Patentee or Applicant of Cited Document	U.S.	Patent Docui	ment			
Examiner Initials	Cite No.1		Num	Number (if known)			 Pages, Columns, Lines, where relevant passages o relevant figures appear 	
	NO.							
						ļ		
						 		
						ļ		
		-						
								
			1					
		EOBEIC	NIDATENT	DOCUME	NTC		<u> </u>	
		FOREIG		Patent Docum		Pages.	Columns, Lines,	
Examiner	Cite	Name of Patentee or				where re	elevant passages elevant figures	T ⁶
Initials	No.1	Applicant of Cited Document	Office ³	Number⁴	KindCode ⁵		appear	'-
*	1,10.							
				+				1
	_			1				
	 			 				
								
			ļ	<u> </u>				
				l				
		OTHER PRIOR ART - N	ON PATEN	T LITERATU	RE DOCUMEN	ITS		
Examiner 's Initials*	No.1 volume-issue number(s), publisher, city and/or country where published							
11		PCT Search Report for PCT/US 01/274	141 dated Ju	ıly18, 2002				
								<u> </u>
								
								Ь

Examiner Signature 91 Date Considered 11/10/03

CONTRACTOR OF THE PARTY OF THE